MEDAREX Inc. and ACTELION Ltd. are rumored to be potential bidders to acquire Oxford Glycosciences PLC OGS, according to West LB Panmure ... MEDAREX Inc. and ACTELION Ltd. are rumored to be potential bidders to acquire Oxford Glycosciences PLC OGS, according to West LB...
PALO ALTO, Calif. -- Frost & Sullivan today announced that it has awarded the 2007 North American Pulmonary Arterial Hypertension PAH Market Leadership of the Year Award to Actelion Pharmaceuticals US, Inc. According to Frost & Sullivan's research, Actelion is the key leader in the U.S. PAH market. Actelion's product...
GENENTECH Inc. and Actelion Ltd. have signed a development and copromotion licensing agreement for tezosentan, and endothelin receptor antagonist used in treating acute heart failure. Genentech ... GENENTECH Inc. and Actelion Ltd. have signed a development and copromotion licensing agreement for tezosentan, and endothelin...
MONTE CARLO, Monaco -- Dr. Jean-Paul Clozel, founder of Switzerland's Actelion Pharmaceuticals Ltd., a pioneering biotechnology company, was last night named the Ernst & Young World Entrepreneur Of The Year 2008 at an awards ceremony held in Monte Carlo's Salle des Etoiles. Clozel was picked from among entrepreneurs representing more...
United Therapeutics Corp. derives almost all of its commercial sales from its top product Remodulin, a treatment for pulmonary arterial hypertension. In 2009, however, the biotechnology company could be drifting into troubled waters. For the six-months ended June 30, Remodulin accounted for approximately 95 percent of the $130.6 million in...